Onsdag 5 Februari | 18:57:10 Europe / Stockholm

Kalender

Tid*
2025-08-29 N/A Kvartalsrapport 2025-Q2
2025-05-15 N/A Årsstämma
2025-03-28 N/A Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-20 - X-dag ordinarie utdelning CANATU 0.00 EUR
2024-06-19 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-06-26 - Årsstämma
2023-05-09 - X-dag ordinarie utdelning CANATU 0.00 EUR
2023-03-02 - Bokslutskommuniké 2022
2022-09-15 - Kvartalsrapport 2022-Q2
2022-05-18 - Årsstämma
2022-05-17 - X-dag ordinarie utdelning CANATU 0.00 EUR

Beskrivning

LandFinland
ListaFirst North Finland
SektorFinans
IndustriInvesteringar
Canatu är ett teknikbolag verksamt inom djupteknologi som skapar kolnanorör (Canatu CNT), relaterade produkter och tillverkningsutrustning för halvledar-, fordons- och medicinsk diagnostikindustri. Bolaget verkar genom två affärsmodeller, för det första genom sina egna reaktorer för att utveckla och tillverka CNT-produkter. För det andra säljer bolaget sina CNT-reaktorer och licensierar dess relaterade teknologi, för att kunder ska kunna producera produkterna själva under en begränsad licens.
2024-09-17 15:00:00

Canatu Plc Company Release 17 September 2024 at 4:00 pm EEST

Canatu Plc – Notification under Chapter 9, Section 10 of the Finnish Securities Markets Act

Canatu Plc has on 17 September 2024 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act, according to which Denis Cherkasov’s indirect holding has exceeded the threshold of five (5) percent of all shares and voting rights in Canatu Plc. According to the notification, the threshold was exceeded on 16 September 2024.

According to the notification, the aggregate indirect holding of Denis Cherkasov has increased to 2,526,275 Canatu Plc’s Series C shares, corresponding to 7.35 percent of all shares and voting rights in Canatu Plc. 

Total position of Denis Cherkasov according to the notification:

 % of shares and voting rights % of shares and voting rights through financial instruments Total of both in % Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached7.357.3534,386,816
Position of previous notification (if applicable)N/AN/AN/A 

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights:

Class/type of shares

ISIN code (if possible)

Number of shares
and voting rights 
% of shares and voting rights
 Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
FI400057806702,526,27507.35
SUBTOTAL A2,526,2757.35

B: Financial instruments according to SMA 9:6a:

Type of
financial instrument
Expiration dateExercise/
Conversion Period
Physical or
cash settlement
Number of
shares and voting rights
% of shares and voting rights
N/AN/AN/AN/AN/AN/A
 SUBTOTAL BN/AN/A

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name% of shares and voting rights% of shares and voting rights through financial instrumentsTotal of both
Denis Cherkasov000
Mymetics Holding (Cyprus) Limited7.3507.35

More information:

Juha Kokkonen

CEO

juha.kokkonen@canatu.com

t. +358 40 543 0367

Certified adviser

Carnegie Investment Bank AB (publ)
tel. +46 (0)73 856 42 65

About Canatu

Canatu (CANATU, Nasdaq First North, Finland) is a fast-growing deep technology company creating advanced carbon nanotubes (Canatu CNTs), related products, and manufacturing equipment for the semiconductor, automotive, and medical diagnostics industries. Canatu partners with forerunner companies, together transforming products for better tomorrows with nano carbon.  

Canatu’s versatile platform technology has broad potential applications. Its current core includes CNT membranes for extreme ultraviolet (EUV) processes in the semiconductor industry, enabling the manufacturing of the most advanced chips, as well as film heaters for advanced driver-assistance systems (ADAS) in the automotive industry. Additionally, electrochemical sensors for medical diagnostics are in the development phase. Canatu’s patented CNT reactors and Dry DepositionTM method yield clean and pristine CNTs. The company operates through two business models: selling CNT products directly, as well as selling CNT reactors and licensing the related technology so that customers can produce CNT products under a limited license.  

Headquartered in Finland, Canatu also operates in the US, Japan, and Taiwan. Founded in 2004 as a spin-off from Aalto University’s Nanomaterials Group, Canatu currently has around 130 employees representing over 30 nationalities, with 20 percent holding or pursuing doctorates. Discover more at www.canatu.com and follow us on LinkedIn